AbbVie Inc

ABBV

Equity

ISIN null / Valor 20145667

New York Stock Exchange, Inc (2025-11-21)

USD 236.28+2.98%

AbbVie Inc
UMushroom community rating:

4.50 2 votes No rating yet

NegativeNeutralPositive

About company

AbbVie Inc. is a global biopharmaceutical company dedicated to researching, developing, and marketing innovative medicines and medical solutions. With a workforce of over 50,000 employees across more than 70 countries, AbbVie focuses on addressing complex health challenges and improving the quality of life for people around the world. The company has a significant presence in research and development (R&D) and manufacturing, with facilities in approximately 20 countries. AbbVie's portfolio includes treatments for over 75 conditions, and its products reach around 50 million people annually in 175 countries. The company also emphasizes collaboration, maintaining over 250 partnerships with biotech firms, universities, nonprofits, and government organizations to advance scientific discovery. AbbVie's commitment to innovation is underscored by its development pipeline, which includes more than 80 compounds, devices, or indications.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

AbbVie Inc. achieved total net revenues of $15.423 billion for the second quarter of 2025, marking a 6.6% increase compared to the same period last year. This growth was driven by significant contributions from the Immunology and Neuroscience segments.

Immunology Performance

The Immunology segment saw a 9.5% operational growth, with revenues reaching $7.631 billion. Notably, Skyrizi revenues surged by 62.2% operationally to $4.423 billion, and Rinvoq revenues increased by 41.8% to $2.028 billion. However, Humira experienced a decline of 58.1%, generating $1.180 billion in revenue.

Adjusted EPS Guidance

AbbVie Inc. has raised its full-year 2025 adjusted diluted earnings per share (EPS) guidance to a range of $11.88 to $12.08, up from the previous range of $11.67 to $11.87. This revision accounts for an unfavorable impact of $0.55 per share related to acquired IPR&D and milestones expenses incurred through the second quarter.

Neuroscience and Oncology Growth

The Neuroscience segment grew by 24.2% operationally, achieving revenues of $2.683 billion. In Oncology, revenues increased by 2.6% to $1.676 billion, supported by products like Venclexta, which saw an 8.5% operational growth.

Strategic Pipeline Progress

AbbVie Inc. highlighted significant pipeline progress with several regulatory approvals and encouraging clinical data. The company continues to invest strategically in promising external innovations, positioning itself for sustained growth in the latter half of the year.

Summarized from source with an LLMView Source

Key figures

37.6%1Y

50.4%3Y

134%5Y

Performance

29.5%1Y

23.4%3Y

22.8%5Y

Volatility